Report | 01-December-2019
Transfusing uncrossmatched red blood cells (RBCs) can be a lifesaving bridge until crossmatched RBCs are available. The risk of using uncrossmatched RBCs is that of hemolysis from unexpected clinically significant antibodies. This study sought to quantify the risk of hemolysis after the transfusion of uncrossmatched RBCs. The records of recipients of uncrossmatched RBCs over approximately 9 months were retrieved from the regional transfusion service. Basic immunohematologic data were recorded
Lisa Radkay,
Darrell J. Triulzi,
Mark H. Yazer
Immunohematology, Volume 28 , ISSUE 2, 39–44
Case report | 09-October-2019
Anti-Ata is a rare alloantibody that can be clinically significant. We report a case of a woman who, after emergency-released uncrossmatched red blood cell transfusion, experienced an acute hemolytic transfusion reaction attributed to anti-Ata. The case presented herein highlights the importance of recognizing that anti-Ata may indeed cause acute hemolytic reactions.
Jay S. Raval,
Sarah K. Harm,
Bethann Wagner,
Darrell J. Triulzi,
Mark H. Yazer
Immunohematology, Volume 32 , ISSUE 4, 140–142
Article | 16-February-2021
crossmatch-compatible PLTs yielded the highest mean CCI of 12.6; however, only two such units were transfused because of the time-consuming effort required to identify such units and also because the patient started to respond to desensitization treatment. After the initiation of IVIG treatment, the mean CCI of uncrossmatched apheresis PLTs and crossmatch-compatible PLTs was comparable (6.1 versus 6.0); therefore, the patient received only uncrossmatched apheresis PLTs after day 110. Figure 1 also shows
S.S. Khatri,
B.R Curtis,
C. Yamada
Immunohematology, Volume 35 , ISSUE 4, 139–144
Case report | 01-December-2019
status, metabolic acidosis, abnormal liver function tests, and a severe coagulopathy. He was successfully resuscitated with uncrossmatched units of group O, D– blood, and after corticosteroid therapy he had complete resolution of his anti-Dmediated hemolysis.
Rachel S. Bercovitz,
Margaret Macy,
Daniel R. Ambruso
Immunohematology, Volume 29 , ISSUE 1, 15–18
Report | 29-October-2019
; uncrossmatched ones. The objective of this study was to evaluate the performance of a LISS-albumin enhancer to intensify antigen-antibody reaction after 5 minutes of 37°C incubation and compare this performance with that of other enhancers, gel, and conventional tube testing. Second, the study evaluated the impact of this method’s implementation in the C:T ratio (crossmatched to transfused RBC units) of a transfusion laboratory. Ninety serum samples containing alloantibodies of potential clinical
Carla Luana Dinardo,
Sílvia Leão Bonifácio,
Alfredo Mendrone Júnior
Immunohematology, Volume 30 , ISSUE 1, 1–5